Immunotherapy for Ovarian Cancer

Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with poor survival rates among patients who have advanced disease despite recent significant advances in […]

Highlights in Ovarian Cancer From the 2021 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2021 ASCO Annual Meeting • June 4-8, 2021 Niraparib Efficacy and Safety in Patients With BRCA-Mutated Ovarian Cancer: […]

Highlights in Ovarian Cancer From the European Society for Medical Oncology Virtual Congress 2020

A Review of Selected Presentations From the ESMO Virtual Congress 2020 Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial Niraparib is an […]

Hem/Onc News

Rucaparib Approved for Maintenance Treatment in Recurrent Ovarian Cancer On April 6, the US Food and Drug Administration (FDA) approved rucaparib (Rubraca, Clovis Oncology) for maintenance […]

Immunotherapy in Ovarian Cancer: Where Are We Now, and Where Are We Going?

H&O What types of immunotherapy have been investigated for use in women with ovarian cancer? AJ The 3 broad areas of immunotherapy that have been […]

Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2017 American Society of Clinical Oncology Annual Meeting • June 1-5, 2017 • Chicago, Illinois Long-Term Benefit of Niraparib Treatment […]

Highlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

A Review of Selected Presentations From the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer March 12-15, 2017 • National Harbor, Maryland Special Reporting […]

Highlights in Ovarian Cancer From the 2016 ESMO Congress

A SPECIAL MEETING REVIEW EDITION A Review of Selected Presentations From the 2016 European Society for Medical Oncology Congress October 7-11, 2016 • Copenhagen, Denmark A […]